Free Trial
NASDAQ:VERV

Verve Therapeutics (VERV) Stock Price, News & Analysis

Verve Therapeutics logo
$3.84 -0.07 (-1.66%)
Closing price 03:58 PM Eastern
Extended Trading
$3.84 0.00 (0.00%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Verve Therapeutics Stock (NASDAQ:VERV)

Key Stats

Today's Range
$3.68
$3.96
50-Day Range
$3.91
$8.63
52-Week Range
$3.68
$9.31
Volume
1.90 million shs
Average Volume
1.47 million shs
Market Capitalization
$341.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.67
Consensus Rating
Buy

Company Overview

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Remove Ads

Verve Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
33rd Percentile Overall Score

VERV MarketRank™: 

Verve Therapeutics scored higher than 33% of companies evaluated by MarketBeat, and ranked 761st out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Verve Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Verve Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Verve Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Verve Therapeutics are expected to decrease in the coming year, from ($2.49) to ($2.83) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Verve Therapeutics is -1.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Verve Therapeutics is -1.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Verve Therapeutics has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Verve Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    23.07% of the float of Verve Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Verve Therapeutics has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Verve Therapeutics has recently increased by 2.76%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Verve Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Verve Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    23.07% of the float of Verve Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Verve Therapeutics has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Verve Therapeutics has recently increased by 2.76%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Verve Therapeutics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Verve Therapeutics this week, compared to 6 articles on an average week.
  • Search Interest

    Only 2 people have searched for VERV on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Verve Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Verve Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.30% of the stock of Verve Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    97.11% of the stock of Verve Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Verve Therapeutics' insider trading history.
Receive VERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VERV Stock News Headlines

8 Best Gene-Editing Stocks to Buy
This almost killed Elon Musk (chilling details emerge)
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
See More Headlines

VERV Stock Analysis - Frequently Asked Questions

Verve Therapeutics' stock was trading at $5.64 at the start of the year. Since then, VERV shares have decreased by 33.0% and is now trading at $3.78.
View the best growth stocks for 2025 here
.

Verve Therapeutics, Inc. (NASDAQ:VERV) posted its earnings results on Thursday, February, 27th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.14. The firm had revenue of $13.08 million for the quarter, compared to analyst estimates of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative trailing twelve-month return on equity of 35.23%.

Verve Therapeutics (VERV) raised $201 million in an IPO on Thursday, June 17th 2021. The company issued 11,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair acted as the underwriters for the IPO.

Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Verve Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

Last Earnings
2/27/2025
Today
4/03/2025
Next Earnings (Estimated)
5/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VERV
Fax
N/A
Employees
110
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.67
High Stock Price Target
$32.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+446.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-200,070,000.00
Net Margins
-807.65%
Pretax Margin
-806.39%

Debt

Sales & Book Value

Annual Sales
$32.33 million
Price / Cash Flow
N/A
Book Value
$7.31 per share
Price / Book
0.52

Miscellaneous

Free Float
68,324,000
Market Cap
$335.65 million
Optionable
Optionable
Beta
1.77
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:VERV) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners